Latanoprost sustained release implant - Pfizer/pSivida

Drug Profile

Latanoprost sustained release implant - Pfizer/pSivida

Alternative Names: Latanoprost slow release insert - Pfizer/pSivida; Latanoprost SR insert - Pfizer/pSivida; Sustained release latanoprost device - Pfizer/pSivida

Latest Information Update: 01 Oct 2015

Price : $50

At a glance

  • Originator Pfizer; pSivida
  • Developer Pfizer; pSivida; University of Kentucky
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 30 Jun 2015 Latanoprost sustained release implant is still in phase I/II trials for Ocular hypertension and Open angle glaucoma in USA
  • 07 Dec 2014 Pfizer terminates phase I/II trial in Open angle glaucoma and Ocular hypertension in USA (NCT01180062)
  • 30 Jun 2014 Phase-I/II development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top